We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$4.46B
This Fund
S&P 500
This Quarter
Est. Return
-10.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
+$436M
(+18%)
Cap. Flow
+$887M
Cap. Flow
% of AUM
31.35%
Top 10 Holdings %
Top 10 Hldgs %
77.97%
Holding
321
New
50
Increased
109
Reduced
123
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$416M |
| 2 |
JD.com
JD
|
+$77.2M |
| 3 |
Pinduoduo
PDD
|
+$71.2M |
| 4 |
Baidu
BIDU
|
+$68.2M |
| 5 |
NetEase
NTES
|
+$43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.5M |
| 2 |
Microsoft
MSFT
|
+$3.76M |
| 3 |
Tesla
TSLA
|
+$2.88M |
| 4 |
United States Brent Oil Fund
BNO
|
+$2.69M |
| 5 |
Invesco DB Oil Fund
DBO
|
+$2.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 60.57% |
| 2 | Communication Services | 21.3% |
| 3 | Technology | 8.32% |
| 4 | Healthcare | 2.45% |
| 5 | Miscellaneous | 2.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
ConocoPhillips
COP
$157B
| $210K | 0.01% |
+2,916
| New | +$212K |
|
252
West Pharmaceutical
WST
$23.7B
| $209K | 0.01% |
+445
| New | +$192K |
|
|
TPTX
253
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $208K | 0.01% |
+4,366
| New | +$195K |
|
254
Broadridge
BR
$20.9B
| $207K | 0.01% |
1,133
-119
| -10% | -$20.9K |
|
255
Monolithic Power Systems
MPWR
$61.7B
| $207K | 0.01% |
420
-55
| -12% | -$28.4K |
|
256
BioCryst Pharmaceuticals
BCRX
$2.51B
| $206K | 0.01% |
14,885
+3,536
| +31% | +$46.8K |
|
257
Fate Therapeutics
FATE
$291M
| $206K | 0.01% |
+3,528
| New | +$200K |
|
258
ResMed
RMD
$34.7B
| $205K | 0.01% |
+787
| New | +$204K |
|
259
Halozyme
HALO
$12B
| $202K | 0.01% |
+5,027
| New | +$188K |
|
260
TJX Companies
TJX
$149B
| $201K | 0.01% |
+2,651
| New | +$184K |
|
261
Hewlett Packard
HPE
$69.3B
| $200K | 0.01% |
12,712
-1,365
| -10% | -$20.6K |
|
262
Kymera Therapeutics
KYMR
$9.82B
| $200K | 0.01% |
+3,150
| New | +$183K |
|
263
Labcorp
LH
$27.2B
| $200K | 0.01% |
+741
| New | +$183K |
|
264
NetApp
NTAP
$36.7B
| $200K | 0.01% |
2,172
-228
| -10% | -$20.5K |
|
265
TG Therapeutics
TGTX
$8.26B
| $199K | 0.01% |
+10,466
| New | +$272K |
|
|
ISEE
266
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $198K | 0.01% |
+11,828
| New | +$194K |
|
|
FOLD
267
DELISTED
Amicus Therapeutics
FOLD
| $195K | 0.01% |
16,869
+1,098
| +7% | +$12.2K |
|
|
BLUE
268
DELISTED
bluebird bio
BLUE
| $193K | 0.01% |
+968
| New | +$228K |
|
269
Exelixis
EXEL
$13.5B
| $189K | 0.01% |
+10,364
| New | +$198K |
|
|
DVAX
270
DELISTED
Dynavax Technologies
DVAX
| $182K | 0.01% |
+12,946
| New | +$213K |
|
271
Ironwood Pharmaceuticals
IRWD
$682M
| $182K | 0.01% |
15,602
+1,472
| +10% | +$18.1K |
|
|
DCPH
272
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $175K | 0.01% |
+17,933
| New | +$337K |
|
|
VXRT
273
DELISTED
Vaxart
VXRT
| $174K | 0.01% |
27,743
+7,940
| +40% | +$54.2K |
|
|
AGEN
274
Agenus
AGEN
$345M
| $173K | 0.01% |
2,730
+1,379
| +102% | +$109K |
|
275
Heron Therapeutics
HRTX
$62M
| $168K | 0.01% |
18,367
+3,562
| +24% | +$36.4K |
|
Similar funds
ACM
HCM
MAM
AP
BP
WSFS
AOI
WA
E Fund Management's Q4 2021 Portfolio in Review
As of Q4 2021, E Fund Management held 321 positions worth $2.83B, up 18% from $2.39B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
E Fund Management deployed $887M of net new capital in Q4 2021, opening 50 new positions and adding to 109 existing holdings. Its largest new stake was Kanzhun: 1,105,207 shares worth $38.5M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 61% of assets, down from 62% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the largest reduction was Apple, an estimated $4.5M trimmed.
- E Fund Management's largest Q4 2021 buy was Kanzhun: 1,105,207 shares worth $38.5M.
- E Fund Management added most to Alibaba in Q4 2021, an estimated $416M increase.
- E Fund Management's biggest Q4 2021 reduction was Apple, cutting an estimated $4.5M.
- E Fund Management fully exited Farfetch Limited Class A Ordinary Shares in Q4 2021, selling an estimated $379K.
- E Fund Management's ten largest holdings make up 78% of its $2.83B portfolio in Q4 2021.
- E Fund Management opened 50 new positions and closed 20 in Q4 2021.
- E Fund Management's portfolio value rose 18% quarter-over-quarter to $2.83B.
Based on E Fund Management's 13F filing for Q4 2021, filed 11 Feb 2022.